Urogenital mycoplasmas, such as pathogen Mycoplasma genitalium and potentially pathogenic Mycoplasma hominis and Ureaplasma spp., cause urogenital diseases. A problem in treating these infections is the resistance of bacteria to antibiotics. Microbiological diagnosis mutations that mediate resistance of M. genitalium is performed by molecular methods such as PCR. Diagnosis of resistance of M. hominis and Ureaplasma spp. to antibiotics is preformed by the method of cultivation. In the master's thesis, we evaluated and compared two PCR tests to determine the susceptibility of M. genitalium to macrolides from two manufacturers, Allplex MG & AziR (Seegene) and Multiplex Tandem PCR Assays (AusDiagnostic). We tested 228 samples of M. genitalium DNA. We found that the AusDiagnostics test has lower sensitivity and specificity for determining the mutation that mediates resistance to macrolides compared to the Seegene test. In the second part of the master's thesis, we validated the new Mycofast RevolutioN 2 test (ELITech Group) and compared it with the older version of the test, Mycofast RevolutioN ATB +, using 100 samples with presence of M. hominis or Ureaplasma spp. We found that the newer test is more suitable for use in the laboratory, as it better complies with CLSI guidelines and contains a better set, concentrations and separation of antibiotics.
|
